Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) has announced that CEO James Dentzer will present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference. The presentation will be available for on-demand viewing starting January 11, 2021, at 6:00 am ET. A live webcast can be accessed on the company's website under "Events & Presentations". Curis focuses on developing cancer therapeutics, with current collaborations on innovative treatments including CA-4948 and CI-8993, both in clinical trials. For more details, visit www.curis.com.

LEXINGTON, Mass., Jan. 5, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference. The presentation will be available for on-demand viewing starting on Monday, January 11, 2021 at 6:00 am ET.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge^® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com. 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright--co-bioconnect-2021-virtual-conference-301201028.html

SOURCE Curis, Inc.

FAQ

When will Curis present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference?

Curis will present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference on January 11, 2021, at 6:00 am ET.

Where can I watch the Curis presentation from the Bioconnect 2021 Conference?

The Curis presentation will be available on-demand on their website starting January 11, 2021, under the 'Events & Presentations' section.

What cancer therapies is Curis currently developing?

Curis is developing therapies including CA-4948 for non-Hodgkin's lymphoma and acute myeloid leukemia, and CI-8993 for solid tumors.

What is the significance of the CA-4948 and CI-8993 clinical trials for Curis?

CA-4948 is in Phase 1 trials for specific blood cancers, while CI-8993 is in Phase 1a/1b trials for solid tumors, highlighting Curis's focus on innovative cancer treatments.

How long will the presentation replay be available on Curis's website?

The replay of the Curis presentation will be available for 90 days following the event.